ALMS progress on envudeucitinib in lupus and psoriasis programs
Envudeucitinib’s phase II lupus trial failed overall, but showed strong efficacy in interferon signature positive patients. Plans are underway for a phase III lupus trial focused on those patients; psoriasis development is progressing toward an NDA.
Envudeucitinib’s phase II lupus trial failed overall because a high proportion of patients were interferon signature negative, but it showed strong efficacy in the signature-positive subgroups. Plans are under way for a phase III trial focused on those patients, while psoriasis development is moving toward NDA submission.